



(51) International Patent Classification:

C07D 471/20 (2006.01) A61K 31/438 (2006.01)
A61P 5/00 (2006.01)

(21) International Application Number:

PCT/GB2024/050502

(22) International Filing Date:

23 February 2024 (23.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2302630.5	23 February 2023 (23.02.2023)	GB
2308196.1	01 June 2023 (01.06.2023)	GB
2313601.3	06 September 2023 (06.09.2023)	GB
2319945.8	22 December 2023 (22.12.2023)	GB

(71) Applicant: **OMASS THERAPEUTICS LIMITED**

[GB/GB]; Building 4000 John Smith Drive, Oxford Business Park South, Oxford OX4 2GX (GB).



(72) Inventors: **BROWN, Giles Albert**; c/o Building 4000 John Smith Drive, Oxford Business Park South, Oxford OX4 2GX (GB). **SANZ, Laia Malet**; c/o Building 4000 John Smith Drive, Oxford Business Park South, OX4 2GX (GB). **TEHAN, Benjamin Gerald**; c/o Building 4000 John Smith

Drive, Oxford Business Park South, Oxford OX4 2GX (GB). **MUSGAARD, Maria**; c/o Building 4000 John Smith Drive, Oxford Business Park South, Oxford OX4 2GX (GB). **ROFFEY, Jonathan Richard Anthony**; c/o Building 4000 John Smith Drive, Oxford Business Park South, Oxford OX4 2GX (GB). **SANDERSON, Adam Jan**; c/o Building 4000 John Smith Drive, Oxford Business Park South, Oxford OX4 2GX (GB).


(74) **Agent: STRATAGEM IPM LIMITED**; Meridian Court, Comberton Road, Toft, Cambridge Cambridgeshire CB23 2RY (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: MC2R MODULATOR COMPOUNDS



Example 134



Example 135




Fig. 1

(57) **Abstract:** The disclosures herein relate to novel compounds of Formula (1): or a salt thereof, wherein J, X, Z, L¹, L², R¹, R², R³, R³ᵃ, R³ᵇ, R³ᶜ and R⁴ are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with the melanocortin subtype-2 receptor (MC2R).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))